Evofem Biosciences Terminates Adare Pharma Deal, Enters New Agreement
Ticker: EVFM · Form: 8-K · Filed: May 2, 2024 · CIK: 1618835
Sentiment: neutral
Topics: material-agreement, termination, partnership
TL;DR
Evofem dumped Adare Pharma and signed a new deal. Details TBD.
AI Summary
Evofem Biosciences, Inc. announced on April 26, 2024, the termination of its Material Definitive Agreement with Adare Pharma Solutions. The company also entered into a new Material Definitive Agreement, the details of which are not fully disclosed in this filing but are related to financial statements and exhibits.
Why It Matters
This filing indicates a significant shift in Evofem's operational partnerships, potentially impacting its supply chain and manufacturing for its products.
Risk Assessment
Risk Level: medium — The termination of a material agreement and entry into a new one suggests potential instability or significant changes in the company's operational strategy and partnerships.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- Adare Pharma Solutions (company) — Party to terminated agreement
- April 26, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the new Material Definitive Agreement Evofem Biosciences entered into?
The filing states that Evofem entered into a new Material Definitive Agreement, but the specific details and nature of this agreement are not fully disclosed in this particular 8-K filing, which primarily focuses on the termination of the previous agreement and the filing of financial statements and exhibits.
What were the reasons for terminating the Material Definitive Agreement with Adare Pharma Solutions?
The provided text of the 8-K filing does not explicitly state the reasons for the termination of the Material Definitive Agreement with Adare Pharma Solutions.
When was the termination of the agreement with Adare Pharma Solutions effective?
The filing reports the termination of the Material Definitive Agreement with Adare Pharma Solutions as an event occurring on April 26, 2024.
Does this filing include updated financial statements for Evofem Biosciences?
Yes, the filing indicates that Financial Statements and Exhibits are part of the information being reported, suggesting updated financial information is included.
What was Evofem Biosciences' former company name?
Evofem Biosciences, Inc.'s former company name was Neothetics, Inc., with a date of name change on September 5, 2014.
Filing Stats: 1,100 words · 4 min read · ~4 pages · Grade level 10.8 · Accepted 2024-05-02 17:28:50
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share EVFM OTCQB Indicate by
- $1,000,000 — ayment to the Company, in the amount of $1,000,000 (the "Initial Payment"), via wire initi
- $2,500,000 — 00, up to a maximum aggregate amount of $2,500,000 or 2,500 shares of Series F-1 Preferred
- $1,500,000 — eries F-1 Preferred Stock. A maximum of $1,500,000 shall be raised prior to June 17, 2024
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex2-1.htm (EX-2.1) — 46KB
- 0001493152-24-017598.txt ( ) — 263KB
- evfm-20240426.xsd (EX-101.SCH) — 3KB
- evfm-20240426_lab.xml (EX-101.LAB) — 33KB
- evfm-20240426_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: May 2, 2024 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer